Finding new drugs to reduce harmful lipid buildup in Alzheimer's disease linked to APOE4.
High-Content Screen to Identify Small Molecule Therapeutics that Reduce Aberrant Lipid Accumulation in APOE4 Alzheimer's Disease
This study is looking at how a specific gene linked to Alzheimer's disease affects fat processing in the brain, and it's trying to find new medications that could help keep brain cells healthy by reducing harmful fat buildup, which could lead to better treatment options for people with Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mcm6 Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11067722 on NIH RePORTER |
What this research studies
This research focuses on understanding how the APOE4 gene, which significantly increases the risk of Alzheimer's disease, affects lipid metabolism in the brain. By using advanced cell models, the team aims to identify small molecule therapeutics that can reduce the harmful accumulation of lipids in oligodendrocytes, the cells responsible for myelinating and protecting neurons. The approach involves high-content screening to discover potential drugs that can restore normal lipid levels and improve brain health. Patients may benefit from new treatment options that specifically target the underlying mechanisms of Alzheimer's disease related to lipid dysregulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a genetic predisposition to Alzheimer's disease, particularly those carrying the APOE4 allele.
Not a fit: Patients without the APOE4 allele or those with other forms of dementia unrelated to lipid metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically address lipid accumulation in Alzheimer's patients, potentially slowing disease progression.
How similar studies have performed: While the specific approach of targeting lipid accumulation in APOE4-related Alzheimer's is novel, similar strategies targeting lipid metabolism have shown promise in other neurological conditions.
Where this research is happening
Lexington, United States
- Mcm6 Therapeutics, INC. — Lexington, United States (Active)
Researchers
- Principal investigator: Lam, Kelvin T — Mcm6 Therapeutics, INC.
- Study coordinator: Lam, Kelvin T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.